

10. McGee, J., Giannakeas, V., Karlan, B., Lubinski, J., Gronwald, J., Rosen, B., McLaughlin, J., Risch, H., Sun, P., Foulkes, W. D., Neuhausen, S. L., Kotsopoulos, J., Narod, S. J., & the Hereditary Ovarian Cancer Clinical Study Group. (2017). Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted? *Gynecologic Oncology*, 145, 346–351.
11. McLaughlin, J. R., Rosen, B., Moody, J., Pal, T., Fan, I., Shaw, P. A., Risch, H. A., Sellers, T. A., Sun, P., & Narod, S. A. (2012). Long term ovarian cancer survival associated with mutation in BRCA1 or BRCA2. *Journal of the National Cancer Institute*, 105(2), 141–148.
12. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) (2017) Genetic/Familial High-Risk Assessment: Breast and Ovarian Version 2.2017 — December 7, 2017.
13. Ozga, M., Aghajanian, C., Myers-Virtue, S., McDonnell, G., Jhanwar, S., Hichenberg, S., & Sulimanoff, I. (2015). A systematic review of ovarian cancer and fear of recurrence. *Palliative & Supportive Care*, 13(6), 1771–1780.
14. Reb, A. M. (2007). Transforming the death sentence: Elements of hope in women with advanced ovarian cancer. *Oncology Nursing Forum*, 34(6), E70–E81.
15. Vencken, P. M., Kriege, M., Hooning, M., Menke-Pluymers, M. B., Heemskerk-Gerritsen, B. A., van Doorn, L. C., et al. (2013). The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling. *Cancer*, 119(5), 955–962.
16. Yang, D., Khan, S., Sun, Y., Hess, K., Shmulevich, I., Sood, A. K., & Zhang, W. (2011). Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. *JAMA*, 306(14), 1557–1565.